• Flagship EXO-OC™ test clinical study nearing completion
• US commercial pathway progressing toward LDT-ready status by December 2026
• CAR-exosome therapeutics program accelerated with focus on GMP cell sources and CDMO selection

INOVIQ Limited released its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2026. Key highlights include:EXO-OC™ Ovarian Cancer Screening Test: The expanded retrospective clinical study is underway, with cancer-control group analysis on track for June 2026 completion. INOVIQ is progressing toward LDT-ready status by December 2026 and advancing US laboratory partnering discussions.CAR-Exosome Therapeutics: Following a scientific review, the program is focused on evaluating GMP-compliant cell sources, selecting CDMO partners, and assessing dual-action approaches to optimize exosome potency. New in vitro ovarian cancer and TNBC data are expected in 2026.EXO-NET® Commercial Momentum: Promega placed its third EXO-NET order, and INOVIQ is advancing discussions with diagnostic companies on custom NETs for higher-value clinical applications.Financial: INOVIQ had A$11.9m cash at 31 March 2026 and is prioritizing capital allocation to the EXO-OC and CAR-exosome programs.Outlook: INOVIQ is focused on delivering near-term data, clinical, and commercial milestones for EXO-OC and the exosome therapeutics program in 2026.

INOVIQ is prioritizing execution, partnering, and scalable commercial pathways to drive shareholder value. Key areas of focus include:- Completion of the EXO-OC™ clinical study including case-controls in June 2026, followed by high-risk and confounding disease groups in H2 CY2026- Progression of EXO-OC™ toward LDT-ready status and US laboratory partnering by December 2026- Acceleration of the CAR-exosome therapeutics program, including manufacturing readiness and preclinical data generation in solid tumours during 2026- Continued discipline in capital allocation, prioritizing programs with the strongest near-term value potential